References

bekhterev

Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева

V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY

2313-70532713-055X

V. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH

10.31363/2313-7053-2019-4-1-36-38

bekhterev-298

Research Article

НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЕ РАБОТЫ

RESEARCH PAPERS

Генетика дофаминэргической системы: сравнение аддикций и болезни Паркинсона

Dopamine Genetics: Substance Use Disorders vs. Parkinson’s Disease

Карл Лин

З.

Carl Lin

Холл

Ф. С.

Hall

F. S.

Бэлл

Р. Л.

Bell

R. L.

Лаборатория Психиатрической Нейрогеномики госпиталя МакЛин и кафедра психиатрии, Медицинская школа ГарвардаСоединённые Штаты АмерикиLaboratory of Psychiatric Neurogenomics at McLean Hospital, and Department of Psychiatry, Harvard Medical SchoolUnited States

Отделение Фармакологии и Экспериментальной терапии, колледж фармакологии и фармацевтических наук, Университет ТоледоСоединённые Штаты АмерикиDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of ToledoUnited States

Отделение психиатрии, Институт психиатрических исследований, Университетская медицинская школа ИндианыСоединённые Штаты АмерикиDepartment of Psychiatry, Institute of Psychiatric Research, Indiana University School of MedicineUnited States

2019

06122019

04-13638

2019

Карл Лин З., Холл Ф.С., Бэлл Р.Л.

Carl Lin Z., Hall F.S., Bell R.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.bekhterevreview.com/jour/article/view/298

Установлено, что расстройства, связанные с употреблением психоактивных веществ (SUDs) и болезнь Паркинсона (PD), среди многих других психоневрологических расстройств являются связанными с дофамином (DA) расстройствами головного мозга с высоким уровнем наследуемости. Тем не менее, неясно, имеют ли эти заболевания общие механизмы формирования генетических рисков. В этом исследовании используется база данных генотипов и фенотипов (dbGaP) путем загрузки связанных исследований геномных ассоциаций (GWAS) для отдельных генотипов / фенотипов. Согласно нашим результатам, дофаминэргическая нейромедиация в значительной степени вовлечена в генетическую этиологию как SUD, так и PD, но гораздо больше в первом случае.

It is established that Substance use disorders (SUDs) and Parkinson’s Disease (PD) among many other neuropsychiatric disorders are dopamine (DA)-related brain disorders with strong heritability. However, it is unclear whether DA-associated genetic risks share commonality across these disorders. This study utilizes the Genotype and Phenotype Database (dbGaP), by downloading related genome-wide association studies (GWAS) for individual genotype/phenotypes. According to our results DA pathways are significantly implicated in the genetic etiology of both SUDs and PD but much more in the former. Epistatic effects may represent a major portion of missing heritability observed in current main effect-oriented GWAS analyses.

болезнь-специифичныйэпистазгенетическая этиологияпропущенная наследственностьнейропсихиатрические заболеванияпути

disease-specificepistasisgenetic etiologymissing heritabilityneuropsychiatric disorderspathways

References1

Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223-33. Epub 2009/06/30. doi: 10.1016/s0140-6736(09)60746-7. PubMed PMID: 19560604.

Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet. 2014;384(9937):45-52. Epub 2014/07/06. doi: 10.1016/s0140-6736(14)60648-6. PubMed PMID: 24996589.

Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287-323. Epub 2015/09/15.

doi: 10.1016/s0140-6736(15)00128-2. PubMed PMID: 26364544; PubMed Central PMCID: PMCPmc4685753.

Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019;393(10190):2493-502. Epub 2019/05/12. doi: 10.1016/s0140-6736(18)32744-2. PubMed PMID: 31076174.

Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, Dua T, et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet. 2015. Epub 2015/10/12. doi: 10.1016/s0140-6736(15)00390-6. PubMed PMID: 26454360.

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858. Epub 2018/11/30. doi: 10.1016/s0140-6736(18)32279-7. PubMed PMID: 30496104; PubMed Central PMCID: PMCPMC6227754.

Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, et al. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. Lancet. 2018;391(10117):241-50. Epub 2017/11/16. doi: 10.1016/s0140-6736(17)31869-x. PubMed PMID: 29137869; PubMed Central PMCID: PMCPMC5803132.

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-88. Epub 2018/11/30. doi: 10.1016/s0140-6736(18)32203-7. PubMed PMID: 30496103; PubMed Central PMCID: PMCPMC6227606.

Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019. Epub 2019/06/30. doi: 10.1016/s01406736(19)30427-1. PubMed PMID: 31248666.

Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nature reviews Genetics. 2005;6(7):521-32. Epub 2005/07/05. doi: 10.1038/nrg1635. PubMed PMID: 15995696.

Zhao Y, Yu J, Zhao J, Chen X, Xiong N, Wang T, et al. Intragenic Transcriptional cis-Antagonism Across SLC6A3. Molecular neurobiology. 2018. Epub 2018/09/28. doi: 10.1007/s12035-018-13575. PubMed PMID: 30259411.

Liu K, Yu J, Zhao J, Zhou Y, Xiong N, Xu J, et al. (AZI2)3’UTR Is a New SLC6A3 Downregulator Associated with an Epistatic Protection Against Substance Use Disorders. Molecular neurobiology. 2018;55(7):5611-22. Epub 2017/10/07. doi: 10.1007/ s12035-017-0781-2. PubMed PMID: 28983843; PubMed Central PMCID: PMCPMC5886844.

Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic case-control association studies. Nature protocols. 2010;5(9):1564-73. Epub 2010/11/19. doi: 10.1038/nprot.2010.116. PubMed PMID: 21085122; PubMed Central PMCID: PMCPmc3025522.

Bahi A, Dreyer JL. No effect of sex on ethanol intake and preference after dopamine transporter (DAT) knockdown in adult mice. Psychopharmacology. 2018. Epub 2018/12/13. doi: 10.1007/ s00213-018-5144-9. PubMed PMID: 30539268.

The authors declare that there are no conflicts of interest present.